Medical Advocates
 

Kaletra Library Service 
Conference Abstracts and Posters
   
  XVII International AIDS Conference
 Mexico City, Mexico


August 03-08, 2008





 
KLS Main Page   KLS Conference Index  Home
Last Update:  September 09, 2008
   Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 
  • A WEEK IN REVIEW FEATURED REPORT
    POSTER
     Week-96 end of trial analysis of antiretroviral-naïve patients randomized to the lopinavir/ritonavir single drug
    arm in the MONARK trial
    J. Ghosn, P. Flandre, C. Delaugerre, et al
         PDF Poster         Abstract
  • POSTER
     Predictors of Persistence with Lopinavir/ritonavir (LPV/r) Soft-Gelatin Capsule-Based Antiretroviral Regimens
    R Rode, Q Feng, T Podsadecki, et al
    PDF Poster     Abstract
  • POSTER
         Trough Lopinavir Concentrations <1 μg/mL Are Not Associated with Virologic Failure in Antiretroviral-Naïve
    Patients Receiving a Lopinavir/ritonavir-Based 3-Drug Regimen
     Y-L Chiu, C Enders Klein, J Li, et al
     PDF Poster        Abstract 
  • POSTER
         Impact of Gender on Response to Lopinavir/ritonavir (LPV/r) Tablets Dosed QD or BID Administered
    with Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) in Antiretroviral-naïve (ARV) Subjects:
         Results from Study M05-730
     B da Silva, D Cohen, S Gibbs, et al
     PDF Poster       Abstract
  • POSTER 
    Comparable HIV-1 Viral Suppression and Immunologic Recovery of White and Non-White
    Antiretroviral-Naïve Subjects Taking Lopinavir/ritonavir (LPV/r) Tablets + Tenofovir Disoproxil Fumarate (TDF)
    and Emtricitabine (FTC) through 48 Weeks
    B da Silva, D Cohen, S Gibbs, et al
    PDF Poster      
  • POSTER
         Lopinavir/ritonavir (LPV/r) in Pregnancy
    SS Roberts, M Martinez, DL.Covington, et al
         PDF Poster
  • Effects of lopinavir/ritonavir-based therapy on the lipograms of young children
     R. Strehlau , A. Coovadia , T. Meyers
  • Resistance to LPV, TPV and DRV according to three different algorithms in samples from highly antiretroviral-therapy
    experienced-patients in Mexico City
     A. Campos, R.A. Rodríguez-Díaz, L.L. Fuentes-Romero, L.E. Soto-Ramírez
  • Pharmacokinetics of lopinavir in the LPV/r-Meltrex formulation compared to the LPV/r-soft gelatine capsule in
    HIV-infected patients
     P. Langmann, M. Leyh, H. Klinker, et al
  • Response to treatment with lopinavir/ritonavir among mexican HIV-infected children and adolescents
         R. Muñoz-Hernandez, D. Jarillo-Quijada, N. Pavia-Ruz, et al
  • Evaluation of adherence to antiretroviral regimen- containing Kaletra in a group of adolescents with chronic HIV-1
    infection from Romania
         t D. Duiculescu A. Blaglosov, A. Luca, et al
  • A new simple and useful immunoenzymatic test to monitoring adherence and through levels of lopinavir in
    HIV-infected children
         R. Rosso, F. Miletich, L. Nulvesu, et al
  • Unexpected high failure rate of lopinavir (LPV/r) monotherapy
     F. Zenger , A. Cusini  , C. Fux,  et al
  • Switching from lopinavir/r capsules to lopinavir/r tablets. Is there an improvement of gastrointestinal complaints?
    C. Koegl, E. Wolf, A. Eberhard, et al
  • A randomised trial of lopinavir/ritonavir (LPV/r) monotherapy vs continued HAART in patients on suppressive therapy
     L. Waters, A. Jackson, K. Singh, et al
  • Safety and tolerability of the lopinavir/ritonavir (LPV/r) tablet in comparison to other protease inhibitors (PIs):
    the SAPIKAT trial
     U.F. Bredeek, B. Williams, R. Rhode, et al
  • Impact of a lopinavir/ritonavir (Kaletra) based second-line antiretroviral therapy regimen on lipid and lipoprotein profiles
    in an African setting
     Z. Gomo, S. Walker, J. Hakim, et al
  • A pilot study assessing once-daily lopinavir/ritonavir (LPV/r) oral solution (OS) with fixed dose emtricitibine/tenofivir
    (FTC/TDF) as the initial HAART in antiretroviral naïve HIV-infected subjects
     S. Schrader, R. Andrade, E. Villarreal-Williams, et al
  • Lopinavir-ritonavir plus nevirapine as a strategy to improve nucleoside-related mitochondrial toxicity in chronically
    treated HIV-infected patients: 48 week follow-up of MULTINEKA study
     E. Negredo, O. Miró, G. Garrabou, et al
  • Different effects on body composition between men and women switching triple therapy with lopinavir-ritonavir (LPV/rtv)
    and two nucleoside analogs (NRTIs) to lopinavir-ritonavir plus nevirapine (NVP) for maintenance therapy of HIV infection:
    MULTINEKA substudy
     C. Estany, E. Negredo, E. Martinez-Lope, et al
 
KLS Main Page   KLS Conference Index  Home

XVII International AIDS Conference